Virology and Immunology of Hepatitis Viruses

  • Authors: Raymond T. Chung, MD; Esperance Anne Kreek Schaefer, MD, MPH (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 7/10/18 (What's New)

Summary

  • Regimens using combinations of DAAs have become the standard of care for HCV
    • DAAs from multiple drug classes, including PIs, NS5A inhibitors, and NS5B inhibitors, are now approved for use in several countries and are recommended by expert guidelines

Action required